Analysis of the initial treatment phase in first-episode psychosis. 1998

P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
Early Psychosis Prevention and Intervention Centre, Parkville, Victoria, Australia. eppic@vicnet.net.au

BACKGROUND The Early Psychosis Prevention and Intervention Centre (EPPIC) commenced operation in Melbourne, Australia, in 1992. It offers a model for management of first-episode psychosis, utilising principles of early detection, low-dose medication and comprehensive psychosocial interventions within the least restrictive setting. METHODS Data were examined from the first three months of treatment for all consecutive people with first-episode psychosis (n = 231) accepted in the programme in 1995-1996. A subsample of patients (n = 120) was assessed comparing clinical ratings with variables of gender, diagnosis, hospitalisation, and medication. RESULTS Hospitalisations were brief, and avoided for a third of the people. Low-dose antipsychotic medication was maintained in both in-patient and community settings. Those people with manic psychosis were more likely to be hospitalised. Hospitalised people received higher antipsychotic dosages, and had a greater rate of reduction in Brief Psychiatric Rating Scale psychotic subscale scores at three months follow-up. Eighty per cent of a representative subsample had responded to treatment and 63% were in remission by the end of the three months. CONCLUSIONS This naturalistic study suggests that the feasibility of implementing the EPPIC model in a range of clinical settings is promising and applicable in practice.

UI MeSH Term Description Entries
D008297 Male Males
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D003156 Community Mental Health Services Diagnostic, therapeutic and preventive mental health services provided for individuals in the community. Community Mental Health Service,Mental Health Services, Community,Assertive Community Treatment,Health Services, Community Mental,Services, Community Mental Health,Services, Mental Health Community,Community Treatment, Assertive,Treatment, Assertive Community
D005260 Female Females
D006760 Hospitalization The confinement of a patient in a hospital. Hospitalizations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
January 2017, Clinical schizophrenia & related psychoses,
P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
July 2003, Schizophrenia research,
P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
January 2015, Turk psikiyatri dergisi = Turkish journal of psychiatry,
P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
November 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
May 2006, The Australian and New Zealand journal of psychiatry,
P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
January 2021, Noro psikiyatri arsivi,
P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
April 2001, Singapore medical journal,
P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
July 2003, Schizophrenia research,
P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
January 1997, Schizophrenia bulletin,
P Power, and K Elkins, and S Adlard, and C Curry, and P McGorry, and S Harrigan
February 2006, World psychiatry : official journal of the World Psychiatric Association (WPA),
Copied contents to your clipboard!